Rivoluzione in casa della società svizzera: nei prossimi 18 mesi saranno eliminati posti di lavoro nel settore della produzione tradizionale, della coordinazione e dello sviluppo. Parallelamente ne creerà altri 350 nel campo dell’alta tecnologia
Of Aboutpharma Online editorial staff – 19 maggio 2017 – Aboutpharma
The company gave some details but said it would close two former production sites: one at the Basel campus and another in Schweizerhalle, also in Basel. Part of the works will be transferred to India. The Swiss union Unia commented underlining the seriousness of the news for the country, especially given the positive economic situation of Novartis and invited the company to rethink the decision. Unia also stated that the restructuring measure affects 162 manufacturing jobs, 109 development jobs and 117 pharmaceutical management roles. It also affects 105 finance, recruiting, IT, sales and infrastructure jobs.
Novartis has announced that it has initiated a process of dialogue and consultation with unions to offer assistance to affected employees. Part of them will be reabsorbed and transferred while some will disappear completely: an employment office will in fact be committed to supporting them for a new placement within or outside the group. There will also be a social plan and an early and voluntary retirement scheme. The 350 jobs that the pharmaceutical giant plans to create at the same time as the workforce reduction in Basel mainly concern the development and production of innovative biotechnological medicines.